What is the FODMAP (Fermentable Oligo-, Di-, Mono-saccharides, and Polyols) diet?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is the FODMAP Diet

The FODMAP diet is a therapeutic three-phase dietary intervention that restricts fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (short-chain carbohydrates) to manage gastrointestinal symptoms, primarily in irritable bowel syndrome (IBS). 1

Definition and Components

The acronym FODMAP stands for:

  • Fermentable Oligosaccharides (fructans and galacto-oligosaccharides)
  • Disaccharides (lactose)
  • Monosaccharides (excess fructose)
  • Polyols (sorbitol, mannitol, xylitol, maltitol) 2

These are poorly absorbed short-chain carbohydrates that undergo rapid fermentation in the gut, producing gas and triggering symptoms in susceptible individuals. 2, 3

Three-Phase Implementation Structure

Phase 1: Restriction (4-6 weeks)

  • Complete elimination of all high-FODMAP foods to determine if symptoms are linked to FODMAP intake 4, 5
  • Patients typically report symptom improvement within 2-6 weeks 5
  • Daily multivitamin supplementation should be considered during this phase 5, 6
  • This phase should not be continued long-term due to potential nutritional inadequacies and negative impacts on the gut microbiome, particularly reducing beneficial bifidobacteria 4, 5

Phase 2: Reintroduction (6-10 weeks)

  • Systematic challenge with foods containing single FODMAPs while maintaining baseline restriction 4, 5
  • Foods are introduced in increasing quantities over 3 days while monitoring symptom responses 5
  • The most common trigger FODMAPs identified during reintroduction are fructans, mannitol, and galacto-oligosaccharides 4, 7
  • Common culprit foods include wheat, milk, onions, garlic, and pulses 5, 8

Phase 3: Personalization

  • Development of an individualized long-term diet based on reintroduction results 4, 5
  • Long-term studies show sustained symptom relief with an adapted FODMAP approach in 50-60% of patients 4, 6

Clinical Positioning and Effectiveness

The low FODMAP diet is recommended as a second-line dietary therapy for IBS when first-line standard dietary advice (regular meal patterns, adequate hydration, limiting alcohol/caffeine, reducing fatty/spicy foods) has failed to provide adequate relief. 1, 4

Network meta-analyses demonstrate the low FODMAP diet is superior to other dietary interventions for reducing abdominal pain, bloating, and improving satisfaction with bowel habits. 4 Approximately 70% of patients respond to the diet, with significant improvements in IBS Symptom Severity Score and quality of life. 5

Patient Selection Criteria

Good Candidates:

  • Patients with moderate to severe gastrointestinal symptoms 1, 4
  • Those with insight into their meal-related symptoms and motivation to make dietary changes 1, 5
  • Individuals willing to follow-up with healthcare providers 5

Poor Candidates:

  • Patients with moderate to severe anxiety or depression 1, 4, 5
  • Those consuming few culprit foods or at risk for malnutrition 1, 5
  • Food insecure individuals 1, 5
  • Patients with eating disorders or uncontrolled psychiatric disorders 1, 5

For patients with substantial psychological comorbidities, a "gentle" or "bottom-up" FODMAP approach focusing on selected high-FODMAP foods rather than complete restriction is recommended. 1, 5

Implementation Requirements

Referral to a registered dietitian nutritionist (RDN) with gastrointestinal expertise is strongly recommended for optimal implementation. 1, 4, 5 The diet is complex and potentially costly, requiring significant patient education and commitment. 4, 5

If a gastrointestinal RDN is not available, alternative resources such as webinars, apps, and leaflets can assist, though these remove the personalized approach and may introduce safety concerns regarding nutritional adequacy. 8

Critical Pitfalls and Caveats

  • Routine screening for eating disorders using tools like the SCOFF questionnaire is critical before starting restrictive diets, as these conditions are common and often overlooked in gastrointestinal patients 6
  • If no symptom improvement occurs within 4-6 weeks, the diet should be discontinued and alternative treatments considered 4, 6
  • The restriction phase must not be continued indefinitely due to potential negative impacts on the intestinal microbiome and nutritional status 4, 5
  • The diet may alter gut microbiome composition, particularly reducing bifidobacteria abundance 4

Mechanism of Action

The primary mechanism involves reducing colonic gas production from fermentation, which can induce pain signaling measurable in the brain. 3 Additional mechanisms may include effects on gastrointestinal epithelial integrity and shifts in microbiome composition and function. 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

All that a physician should know about FODMAPs.

Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2019

Research

Low FODMAP diet in irritable bowel syndrome: a review of recent clinical trials and meta-analyses.

Current opinion in clinical nutrition and metabolic care, 2022

Guideline

Low FODMAP Diet for Irritable Bowel Syndrome

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Implementing the Low-FODMAP Diet for Irritable Bowel Syndrome

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Low FODMAP Diet for Managing SIBO Symptoms

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

All FODMAPs Aren't Created Equal: Results of a Randomized Reintroduction Trial in Patients With Irritable Bowel Syndrome.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.